About

Marc Ferrer is a prolific researcher specializing in high-throughput screening (HTS) technologies, drug discovery, and chemical biology, with contributions that have meaningfully advanced how scientists identify and characterize therapeutic candidates at scale. His work spans multiple cutting-edge domains, including lipid kinase inhibition, G protein-coupled receptor (GPCR) pharmacology, drug combination strategies, and RNA interference methodologies. Among his notable contributions, Ferrer led a large-scale screen identifying chemical inhibitors of phosphatidylinositol 4-kinase type II alpha (PI4KIIα), shedding light on lipid transfer regulation at membrane contact sites — a finding with implications for multiple disease pathways. His development of a 1,536-well [³⁵S]GTPγS scintillation proximity assay enabled ultra-high-throughput profiling of orphan Gαi-coupled GPCRs, demonstrating his technical ingenuity in tackling historically difficult drug targets. His work on automated siRNA transfection protocols for genome-scale screens and methodological frameworks for screening drug combinations further underscores his commitment to building efficient, scalable research infrastructure. Collectively accumulating nearly 90 citations, Ferrer's research has provided the scientific community with powerful tools and platforms that continue to accelerate early-stage drug discovery efforts across academia and industry.

Research Focus

Key Achievements

4
H-Index
4
Papers
86
Total Citations
22
Avg Citations/Paper
🏆 Most Cited Paper
A large scale high-throughput screen identifies chemical inhibitors of phosphatidylinositol 4-kinase type II alpha
28 citations · 2019
📈 Most Prolific Year: 2019 (2 Papers)
🤝 Key Collaborators: 34
🏛 Institutions: National Center for Advancing Translational Sciences, Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago